Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EIK1001 + Pembrolizumab + Chemotherapy in Stage 4 NSCLC
NCT07365319Phase 3Recruiting
- Sponsor
- Eikon Therapeutics
- Start
- Jun 2026
- Primary completion
- Dec 2035
- Countries
- 11
01
Overview
A Phase 3 trial of BDB001 in non-small cell lung cancer (NSCLC), sponsored by Eikon Therapeutics. Started Jun 2026; status: recruiting.
02
Drugs
BDB001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07365319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07365319.